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Objective: To evaluate whether endovascular thrombectomy combined
with intravenous thrombolysis is superior to the standard treatment of
intravenous thrombolysis for the treatment of ischemic stroke.
Methods: A meta-analysis of 12 studies obtained by searching PubMed
and Web of Science database was performed to determine whether the
difference in mortality (within 7 days or 90 days), functional outcome
(modified Rankin Scale, 0–2), hemorrhage (symptomatic intracerebral
hemorrhage, and subarachnoid hemorrhage), and recurrent ischemic
stroke rate at 90 days between patients who underwent mechanical
intravenous thrombolysis with (intervention) and without (control)
endovascular thrombectomy.
Results: As compared with the control group, patients in the intervention group had lower 90-day mortality [summary risk ratio (RR) =
0.83, 95% confidence interval (CI): 0.69–0.99; n = 1309/1070], higher
recanalization rate (RR = 2.24, 95% CI: 1.97–2.56; n = 504/497), better
functional outcome (modified Rankin score: 0–2; RR = 1.41, 95% CI:
1.29–1.54; n = 1702/1502), and higher rate of subarachnoid hemorrhage
(RR = 2.40, 95% CI: 1.45–3.99; n = 1046/875) without significant difference
in the 7-day mortality (RR = 1.12, 95% CI: 0.84–1.50; n = 951/773),
symptomatic intracranial hemorrhage (RR = 1.12, 95% CI: 0.82–1.54;
n = 1707/1507), or recurrent ischemic stroke (RR = 0.90, 95% CI: 0.52–1.54;
n = 718/506).
Conclusion: Our results demonstrated that patients in the intervention
group had lower mortality and better functional outcomes than the
control group. Although patients in the intervention group had a higher
rate of subarachnoid hemorrhage; hence, endovascular thrombectomy
combined with intravenous thrombolysis is still a beneficial intervention
for a defined population of stroke patients.
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Introduction

Stroke is known as the first leading cause of death
and disability worldwide [1]. Intravenous (IV)
tissue plasminogen activator (tPA) is currently
the only clinical treatment method for ischemic
stroke [2]. Unfortunately, effective vascular
recanalization was observed in only 21% of
patients who received tPA within a 4.5-h time
window [3]. Endovascular therapy was established
to improve the prognosis of stroke patients [4].
Several randomized clinical trials (RCTs) have
demonstrated that endovascular thrombectomy,
when combined with IV thrombolysis, is superior
to the standard treatment of IV thrombolysis
alone for the treatment of ischemic stroke [5–16].
Previously, several meta-analyses have also
compared endovascular therapy with the usual
IV t-PA therapy in terms of mortality, functional
outcome, hemorrhage, and recurrent ischemic
stroke [17–19]. However, they are not examined
in detail; therefore, we rigorously performed
this updated and more detailed meta-analysis to
compare endovascular thrombectomy and control
groups to date.

2

Methods

2.1

Search strategy

A meta-analysis was conducted based on the
Cochrane Reviews guidelines and the Preferred
Reporting Items for Systematic Reviews and
Meta-Analysis checklist [20]. The PubMed and
Cochrane Library (from January 1, 2010 to
January 1, 2020) were searched on May 9, 2020.
The search strategy used is: (thrombectomy) or
(embolectomy) or (thrombolytic therapy) and
(intra-arterial) or (local) or (fibrinolysis) or
(thrombolysis) or (urokinase) or (pro-urokinase)
or (tissue plasminogen activator) or (streptokinase)
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and (cerebrovascular disease) or (stroke) or
(cerebrovascular attack) or (brain attack) or (brain
infarct). Published languages are limited to
English. All retrieved articles are clinical articles.
2.2

Inclusion and exclusion criteria

All abstracts and titles were screened by three
independent authors (Jia Feng, Zhihan Zhu, and
Ahmed Waqas) to select eligible clinical articles.
Studies that met the following inclusion criteria
were included: (1) clinical studies; (2) endovascular
thrombectomy combined with IV thrombolysis
and IV thrombolysis alone; (3) outcome reported
as either mortality, hemorrhage (symptomatic
intracerebral hemorrhage and subarachnoid
hemorrhage), functional outcome (modified
Rankin Scale, 0–2), or recurrent ischemic stroke;
and (4) the number of patients per group
were indicated within the publication. We also
excluded non-clinical studies, literature reviews,
meta-analysis, meeting abstracts, case reports,
repeated studies, experimental model researches,
and studies on other diseases.
2.3

Data extraction

Three authors independently screened the
literature according to the inclusion and exclusion
criteria, extracted data, and assessed the risk
of bias. We obtained the following data: year of
publication, single/multicenter, number of patients
(intervention vs. control groups), patient age,
gender, the National Institutes of Health Stroke
Scale score, and the time allowed toward treatment
from the symptom onset to the follow-up.
2.4

Quality assessment and publication bias

The quality of each study was assessed
independently by the same two investigators
using the Risk of Bias Tool developed by the
Cochrane Collaboration [21]. For each RCT, the
investigators freely scored low, high, and unclear
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risks according to the following rules: sequence
generation, allocation concealment, blinding of
participants and personnel and blinding of the
outcome assessment, incomplete outcome data,
selective reporting, and other potential sources
of bias. Funnel plot and Egger’s test [22] were
used to detect publication bias; no publication
bias was identified with a p < 0.05.
2.5

Statistical analysis

All analyses were performed using STATA 15.0
and Review Manager (RevMan version 5.3)
software, dichotomous data from the published
studies were used to generate risk ratios (RRs)
with 95% confidence intervals (CIs), and a metaanalysis was performed using a Mantel–Haenszel
fixed-effects model to calculate a summary RR
with 95% CI. P ≤ 0.05 incidicates a statistical
significance. Spearman correlation analysis was
used to test heterogeneity caused by the threshold

effect; if I² > 75% and p > 0.05, a meta-regression
analysis was used to determine the sources of
heterogeneity.

3
3.1

Results
Study characteristics

A total of 12 RCTs were identified from 1845
publications (503 from PubMed and 1342 from
Web of Science) for this meta-analysis. The
numbers of patients in the endovascular
thrombectomy treatment group and control
group were 1756 and 1544, respectively (Fig. 1).
Collectively, these 12 RCTs investigated a
total of 3300 patients to receive endovascular
thrombectomy with IV t-PA or IV t-PA alone
(Table 1). Sample sizes ranged from 20 to 500.
EASI was a single-center study, and others are
multicenter studies. The follow-up time for
SYNTHESIS is only 7 days, and the remaining

Fig. 1 Flow diagram for study selection in a meta-analysis.
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Table 1 Baseline characteristics of studies included in this meta-analysis.

Year

Single/
multicenter

2013

Multicenter

IMS III [6]

2013

Study [Ref.#]

MR RESCUE: penumbral [5]
MR RESCUE: non-penumbral [5]

n*

Age*
(years)

Male*
(%)

34/34

66 ± 13/66 ± 17

50/44

30/20

62 ± 12/69 ± 16

43/60

Multicenter 434/222

69/68

NIHSS*

Allowed time to
Length of
treatment
follow-up
from symptom
(d)
onset (h)

NR

8

90

50/55

17/16

3

90

SYNTHESIS [7]

2013

Multicenter 181/181

66 ± 11/67 ± 11

59/57

13/13

6

7

SWIFT PRIM [8]

2015

Multicenter

98/98

65 ± 13/66 ± 11

55/47

17/17

6

90

EXTEND-IA [9]

2015

Multicenter

35/35

69 ± 12/70 ± 12

49/49

17/13

4.5

90

ESCAPE [10]

2015

Multicenter 165/150

71/70

48/47

16/17

12¶

90

REVASCAT [11]

2015

Multicenter 103/103

66 ± 11/67 ± 10

53/52

17/17

8

90

THRACE [12]

2016

Multicenter 204/208

66/68

57/50

18/17

5

90

MR CLEAN [13]

2017

Multicenter 233/267

66/66

58/59

17/18

6

90

EASI [14]

¶

2017 Single center

40/37

74/71

45/50

18/20

6

90

DAWN [15]

2018

Multicenter

107/99

69 ± 14/71 ± 13

39/52

17/17

6–24

90

DEFUSE 3 [16]

2018

Multicenter

92/90

70/71

50/49

16/16

6–16

90

Values are mean ± SD unless otherwise indicated.
* Values are presented for endovascular thrombectomy/intravenous thrombolysis alone groups.
¶

The rtPA must be administered within 4.5 h.

Abbreviations: NIHSS, National Institutes of Health Stroke Scale; NR, not reported; MR RESCUE, Mechanical Retrieval and Recanalization
of Stroke Clots Using Embolectomy; IMS III, Third Interventional Management of Stroke; SYNTHESISA, A Randomized Controlled Trial
Between Loco-regional Intra-arterial (IA) and Systemic Intravenous (IV) Thrombolysis with Alteplase in Acute Ischemic Stroke; SWIFT
PRIME, Solitaire FR with the Intention for Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke; EXTENDA-IA,
Extending the Time for Thrombolysis in Emergency Neurological Defificits–Intra-arterial; ESCAPE, Endovascular Treatment for Small
Core and Anterior Circulation Proximal Occlusion with Emphasis on Minimizing CT to Recanalization Times; REVASCAT, Randomized
Trial of Revascularization with Solitaire FR Device versus Best Medical Therapy in the Treatment of Acute Stroke Due to Anterior
Circulation Large Vessel Occlusion Presenting within Eight Hours of Symptom Onset; THRACE, Trial and Cost Effectiveness Evaluation
of Intra-arterial Thrombectomy in Acute Ischemic Stroke; MR CLEAN, Multicenter Randomized Clinical Trial of Endovascular Treatment
for Acute Ischemic Stroke in the Netherlands; EASI, Endovascular Acute Stroke Intervention Trial; DAWN, DWI or CTP Assessment with
Clinical Mismatch in the Triage of Wake Up and Late Presenting Strokes Undergoing Neurointervention; DEFUSE 3, Endovascular Therapy
Following Imaging Evaluation for Ischemic Stroke 3.

studies were 90 days. Mainly, the MR RESCUE
study includes two parts of data: penumbral
and non-penumbral pattern data. Here only the
penumbral pattern data will be included in this
meta-analysis.

bias using both the Funnel plot [Fig. 3(A)] and
Egger’s test [p = 0.291; Fig. 3(B)].

3.2

All 12 RCTs reported mortality, 4 of which
reported 7-day mortality and 11 90-day mortality.
We performed a meta-analysis on the 7- and
90-day mortality, respectively. The meta-analysis
results demonstrated a higher but non-significant
RR for the 7-day mortality [RR = 1.12, 95% CI:
0.84–1.50, I² = 0%; Fig. 4(A)] in the intervention

Quality assessment and publication bias

According to the Cochrane Risk of Bias Tool
assessment, 10 RCTs were evaluated to obtain
a low risk of bias, whereas 2 RCTs (EASI and
TRANCE) were assessed to have a moderate
risk of bias (Fig. 2). We did not find publication

3.3
3.3.1

Meta-analysis
Mortality
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Fig. 2 Assessment of the risk of bias using the Cochrane Risk of Bias Tool.

Fig. 3 Publication bias assessment using Funnel plot (A) and Egger’s test (B).

group than that in the control group, indicating
that endovascular thrombectomy cannot improve
the short-term survival prognosis. However, with
the extension of the follow-up time to 90 days,
the 90-day mortality of the intervention group
was significantly lower than that of the control
group [RR = 0.83, 95% CI: 0.69–0.99, I² = 0%;
Fig. 4(B)].

3.3.2

Recanalization

Among the 12 RCTs, 6 reported recanalization,
which can be seen from the meta-analysis results
compared with the control group. The intervention
group has a significantly higher RR for
recanalization (RR, 2.24, 95% CI: 1.97–2.56, I² =
69.8%; Fig. 5), indicating that patients receiving
Journal of Neurorestoratology
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Fig. 4 Meta-analyses of comparison between the intervention and control groups on a 7-day mortality (A) and a 90-day
mortality (B).

Fig. 5 Meta-analyses of comparison between the intervention and control groups on recanalization.
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Fig. 6 Meta-analyses of comparison between the intervention and control groups on the functional outcome (modified
Rankin score, 0–2).

endovascular therapy can obtain a higher
revascularization rate; therefore, they may receive
more top health benefits and higher quality of life
in subsequent rehabilitation treatments.
3.3.3
0–2)

Functional outcome (Modified Rankin Score,

Functional outcome was reported in all 12 RCTs.
The meta-analysis results showed that compared
with the control group, the intervention group
had a significantly higher RR for the good
functional outcome (RR = 1.41, 95% CI: 1.29–1.54,
I² = 78%; Fig. 6), indicating that, in all trials,
patients randomized to endovascular thrombectomy therapy with IV t-PA had a significantly
higher functional independence.
3.3.4

analysis demonstrated that the endovascular
thrombectomy group had a significantly lower
RR for subarachnoid hemorrhage [RR = 2.40,
95% CI: 1.45–3.99, I² = 0%, P = 0.0007; Fig. 7(A)],
but non-significant RR for symptomatic intracerebral hemorrhage [RR = 1.12, 95% CI: 0.82–1.54,
I² = 0%; Fig. 7(B)].
3.3.5

Recurrent ischemic stroke

According to the results of 3 RCTs (IMS III,
SYNTHESIS, REVSCAT), the risk of recurrent
stroke at 90 days was non-significantly lower with
endovascular thrombectomy (RR = 0.90, 95% CI:
0.52–1.54, I² = 0%; Fig. 8).

4 Discussion

Hemorrhage

All 12 RCTs reported hemorrhage, 5 of which
reported subarachnoid hemorrhage and 12
reported symptomatic intracerebral hemorrhage,
and then, we performed a meta-analysis on the
subarachnoid and symptomatic intracerebral
hemorrhage, respectively. The results of meta-

4.1

Interpretation of study results

Our study was designed to assess the benefits
and risks of using endovascular thrombectomy
combined with IV thrombolysis vs. standard
treatment of IV thrombolysis alone for the
treatment of ischemic stroke. Endovascular
Journal of Neurorestoratology
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Fig. 8 Meta-analyses of comparison between the intervention and control groups on recurrent ischemic stroke.

Fig. 7

Meta-analyses of comparison between the intervention and control group on subarachnoid hemorrhage (A) and

symptomatic intracranial hemorrhage (B).
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thrombectomy therapy was found to be associated
with lower mortality, higher recanalization rate,
better functional outcome (mRs 0–2), a similar
risk of symptomatic intracranial hemorrhage, and
recurrent ischemic stroke rate at 90 days than IV
thrombolysis alone. Furthermore, no significant
difference was observed in the 7-day mortality
between the two treatment groups.
The recent publication of RCTs included in
our meta-analysis resulted in updates to the
American Heart Association/American Stroke
Association guidelines for the management of
acute ischemic stroke, which expanded the role
of endovascular thrombectomy in assisting IV
thrombolysis for the treatment of acute ischemic
stroke, and these guidelines state that endovascular
thrombectomy should be used within 6 h of
symptom onset [23]. Even so, IV thrombolysis
remains the first clinical choice for the treatment
of acute ischemic stroke. However, only < 30%
of patients can receive effective IV thrombolysis
within the recommended treatment time window
[24]. Although endovascular thrombectomy is
beneficial, endovascular thrombectomy cannot be
fully applied as the treatment for acute ischemic
stroke due to the technical limitations. More
studies may need to further explore the superiority
of endovascular thrombectomy for the treatment
of acute ischemic stroke and provide a theoretical
basis for the future application of endovascular
thrombectomy in clinical medicine.
Before this, several meta-analyses had discussed
the pros and cons of intravascular treatment
of stroke; however, they were not sufficiently
detailed and systematic [17–19]. Therefore, in this
analysis, we conducted a more comprehensive
and systematic review of endovascula r
thrombectomy treatment of stroke. Our results
showed that endovascular thrombectomy,
combined with IV thrombolysis, was associated
with a similar risk of symptomatic intracranial
hemorrhage and recurrent stroke. Interestingly,

the endovascular therapy did not significantly
increase the risk of symptomatic intracranial
hemorrhage but may reduce the incidence of
recurrent stroke. More large-scale studies may
be needed to clarify the relationship between
endovascular treatment and recurrent stroke in
the future.
According to the results of this meta-analysis,
patients receiving endovascular thrombectomy
combined with IV thrombolysis can achieve
lower mortality and better functional outcome
than IV thrombolysis. Then, we can conclude that
endovascular thrombectomy combined with IV
thrombolysis is superior to standard treatment
of IV thrombolysis alone for the treatment of
ischemic stroke.
4.2

Limitations

This study has some limitations. First, individual
patient data is lacking. Second, although we
have tested the publication bias about all included
studies, as with all meta-analyses, a publication
bias is possible in this study. Third, there are two
parts of data in the study of MR RESCURE [5],
penumbra pattern and non-penumbra designs.
We only included the penumbra pattern data in
our study, which may lead to reporting bias.

5

Conclusions

Our results demonstrated that patients who
underwent vascular thrombectomy combined
with IV thrombolysis had lower mortality and
better functional outcomes but no increased
risk of symptomatic intracranial hemorrhage
or recurrent stroke compared with the standard
treatment of IV thrombolysis alone for the
treatment of ischemic stroke.
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